[
    [
        {
            "time": "",
            "original_text": "里昂：予泰格医药(3347.HK)“买入”评级目标价136.38港元",
            "features": {
                "keywords": [
                    "里昂",
                    "泰格医药",
                    "买入",
                    "评级",
                    "目标价",
                    "136.38港元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "里昂：予泰格医药(3347.HK)“买入”评级目标价136.38港元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]